Search filters

List of works by Michel Delforge

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

scientific article

An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

scholarly article by Jo Caers et al published 31 August 2018 in Haematologica

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma

scientific article published on 14 April 2016

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

scientific article published on 03 June 2019

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

scientific article published on 22 August 2019

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

article

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

scientific article

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

scientific article

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

scientific article published on 20 May 2016

European perspective on multiple myeloma treatment strategies in 2014

scientific article

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

scientific article

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

article

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

scientific article published on 17 November 2017

Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.

scientific article published on 7 May 2012

How I manage the toxicities of myeloma drugs.

scientific article published on 8 March 2017

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

scientific article

Insights on Multiple Myeloma Treatment Strategies

scientific article published on 27 December 2018

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

scientific article published on September 2014

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.

scientific article published on 14 December 2012

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

scientific article published on 26 March 2011

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

scientific article published on 01 August 2019

Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

scientific article published on 10 December 2012

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials

scientific article

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

scientific article

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

scientific article published on 25 April 2016

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

scientific article published on 2 May 2018

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

scientific article published on 19 August 2020

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

scientific article

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

scientific article

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

scientific article

Paulina is supported by:

About Paulina

Help